




RealRate

# PHARMACEUTICAL 2017

## Traverse Therapeutics Inc. Rank 112 of 292





RealRate

# PHARMACEUTICAL 2017

## Traverse Therapeutics Inc. Rank 112 of 292



The relative strengths and weaknesses of Traverse Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Traverse Therapeutics Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 56% points. The greatest weakness of Traverse Therapeutics Inc. is the variable Other Liabilities, reducing the Economic Capital Ratio by 60% points.

The company's Economic Capital Ratio, given in the ranking table, is 130%, being 127% points above the market average of 2.9%.

Input Variable	Value in 1000 USD
Assets, Current	332,352
Cost of Goods Sold	0
Intangible Assets	182,979
Liabilities, Current	83,262
Liabilities, Non-Current	4,010
Other Assets	7,364
Other Compr. Net Income	192
Other Expenses	18,470
Other Liabilities	130,243
Other Net Income	632
Other Revenues	133,591
Property and Equipment	2,587
Research and Development	70,853
Selling, General and Administrative Expense	92,803

Output Variable	Value in 1000 USD
Assets	525,282
Liabilities	217,515
Expenses	182,126
Revenues	133,591
Stockholders Equity	307,767
Net Income	-47,903
Comprehensive Net Income	-47,807
Economic Capital Ratio	130%